A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)

Summary

This is a Phase Ⅰ/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and above Myelodysplastic Syndrome (MDS) Patients after Failure of Hypomethylating Agent (HMA)-based Therapy.

Timeline

Start

2021-02-23

Primary completion

2023-09-19

Completion

2023-09-19

Outcome

Outcome not reported

Stopped (Business): “The study was stopped early because the sponsor decided to change the study-drug development strategy”

Drugs

Indications